Kernal Biologics receives USD 48 Million from ARPA-H
The funding received by Kernal Biologics from ARPA-H is to develop lower cost in vivo CAR T-cell therapies for hematological cancers.
CAR T-cell Therapies | 09/10/2025 | By Dineshwori | 155
Galapagos, BCA to Boost Decentralized CAR-T Manufacturing Network in US
Galapagos has inked a strategic partnership with Blood Centers of America (BCA) for the decentralized manufacturing of Galapagos’ CAR-T cell therapies through BCA’s network in the US.
CAR-T Cell Therapies | 17/05/2024 | By Aishwarya | 281
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy